FASgen Announces New Research Discoveries in L...( BALTIMORE Dec. 28 /- FASgen is pl...),Health

BALTIMORE, Dec. 28 /PRNewswire/ -- FASgen is pleased to report the publication of important research results for lung cancer treatment using FAS093, one of the Company's proprietary compounds. In a long-standing cooperation with The Johns Hopkins Oncology Center, FASgen supported research into the selective inhibition of fatty acid synthase (FASi) at the Hopkins Oncology Center as a potential therapeutic agent against various forms of solid tumor cancers. In the recently reported study results, researchers at the Hopkins Oncology Center found that FAS093 significantly inhibited growth of several different xenograft tumors from human NSCLC cell lines. These extremely interesting results appear in the article, "Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment," Gabrielson et al, Clin Cancer Res 200l, 13(23) 7139-7145 (Dec. 1, 2007).

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at http://www.fasgen.com